Trials / Recruiting
RecruitingNCT07213609
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK5460025 | GSK5460025 will be administered |
Timeline
- Start date
- 2025-10-20
- Primary completion
- 2028-09-28
- Completion
- 2028-10-27
- First posted
- 2025-10-09
- Last updated
- 2026-03-23
Locations
9 sites across 3 countries: United States, Canada, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07213609. Inclusion in this directory is not an endorsement.